Researchers have developed a novel peptide with a prolonged half-life that has demonstrated success in rhesus monkeys and mice for inhibiting HIV infections.
List view / Grid view
Filter the results
HIV is a disease still common in sub-Saharan Africa despite global research since 1982. This article delves into the trends, opportunities and key players in HIV research, exploring future possibilities for treating the disease.
Researchers have created two new cellular models that can be used in the study of ocular diseases and drug testing.
Isolated components found in the Saussurea controversa plant have antimicrobial and regenerative properties which could lead to a treatment for bone diseases.
A new study has demonstrated that NLRP3 inflammasome directly drives tau pathology in neurodegenerative diseases and Alzheimer's disease.
Researchers have found that soft tissue sarcoma cells stop a key metabolic process which allows them to spread and restarting that process could leave these cancers vulnerable treatments.
A new signalling pathway has been identified that may help further the understanding of blood clot formation in cancer patients and presents a new drug target for reducing cancer-associated complications.
A novel peptide has been discovered that attacks gram negative bacteria at a previously unknown site of action which presents a promising lead substance for the development of a new antibiotic.
Researchers have developed a vaccine for HIV that has shown success in rabbits, by neutralising a wide range of HIV strains using bnAbs.
A new discovery on how the immune system responds to malaria infection could lead to better treatments for hepatitis C, HIV and lupus.
On 5-6 November, ACC Liverpool hosted the ELRIG Drug Discovery event, which allowed R&D professionals to come together and discuss the latest industry developments.
A new rabies vaccine strategy enhanced the speed and magnitude of the anti-rabies antibody responses and could improve the efficacy of currently used vaccines.
A new discovery that leukaemia type B cells can transform into different cells through epigenetic changes could lead to more effective therapies.